Cell-Surface PCNA Is Co-Expressed with Biomarkers of Stemness and Immunosuppression in Glioblastoma
Cancers · 06.12.2025 · 17 (24) · 3903
DOI: 10.3390/cancers17243903 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 06.12.2025. Verfasst von Luke C Cooksey und 6 weiteren Autor:innen. Beteiligte Einrichtung: Texas College of Osteopathic Medicine, UNT Health, Fort Worth, TX 76107, USA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Prevention and Research Institute of Texas, NIH T32 Neurobiology of Aging and Alzheimer's Disease Fellowship, UNT Health MIG Department.
Abstract (Originalsprache)
Background/Objectives: Glioblastoma (GBM) is a lethal form of primary brain tumor. There has been minimal improvement in overall GBM survival in recent years. To increase survival in patients with GBM, it is important to study novel GBM molecular antigens to form the basis of better diagnostics, prognostic measures, and therapeutic advancements. Our goal is to find more robust GBM-specific antigenic biomarkers to eventually improve GBM outcomes. Here, we initiated an investigation into cell-surface PCNA (csPCNA), a potential GBM biomarker and antigenic target.
Methods
We utilized flow cytometry, imaging flow cytometry, and cell-surface Western blot to identify the expression of csPCNA on GBM cell lines (LN-229, LN-18) and a primary patient-derived tumor specimen. We then employed flow cytometry to study the associative co-expression of csPCNA with other biomarkers of GBM stem cells (CD44, CD49f) and GBM immunosuppression (PD-L1, TGFβRII).
Results
We elucidated that LN-229, LN-18, and the primary GBM patient cells express csPCNA. We found that csPCNA is co-expressed with CD44, CD49f, PD-L1, and TGFβRII on the primary patient-derived GBM specimen.
Conclusions
Our findings that csPCNA is expressed in GBM and is co-expressed with stem cell and immunosuppressive biomarkers indicate that csPCNA may be a potentially useful clinical–pathological biomarker for GBM stemness and immunosuppression.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Texas College of Osteopathic Medicine, UNT Health, Fort Worth, TX 76107, USA.
- Department of Microbiology, Immunology and Genetics, College of Biomedical and Translational Sciences, UNT Health, Fort Worth, TX 76107, USA.
ORCID-Profile: Luke C Cooksey, Ezek Mathew, Nirupama A Sabnis, Porunelloor A Mathew
Förderung
- Cancer Prevention and Research Institute of Texas
- NIH T32 Neurobiology of Aging and Alzheimer's Disease Fellowship
- UNT Health MIG Department
- NIH T32 Neurobiology of Aging and Alzheimer’s Disease Fellowship
- UNT Health Department of Microbiology, Immunology, and Genetics
Zitieren
APA
Cooksey, L. C., Hoteit, T., Mathew, E., Sabnis, N. A., Dickerman, R. D., Chaudhary, P., & Mathew, P. A. (2025). Cell-Surface PCNA Is Co-Expressed with Biomarkers of Stemness and Immunosuppression in Glioblastoma. Cancers, 17(24), 3903. https://doi.org/10.3390/cancers17243903
Vancouver
Cooksey LC, Hoteit T, Mathew E, Sabnis NA, Dickerman RD, Chaudhary P, et al. Cell-Surface PCNA Is Co-Expressed with Biomarkers of Stemness and Immunosuppression in Glioblastoma. Cancers. 2025;17(24):3903. doi:10.3390/cancers17243903
BibTeX
@article{Cooksey2025,
author = {Cooksey, Luke C and Hoteit, Tamara and Mathew, Ezek and Sabnis, Nirupama A and Dickerman, Rob D and Chaudhary, Pankaj and Mathew, Porunelloor A},
title = {Cell-Surface PCNA Is Co-Expressed with Biomarkers of Stemness and Immunosuppression in Glioblastoma},
journal = {Cancers},
year = {2025},
volume = {17},
number = {24},
pages = {3903},
doi = {10.3390/cancers17243903}
}
EUVIMED